The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.
VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.
SLEEP 2026 | Rethinking restless legs syndrome treatment: the shift beyond dopamine agonists
Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, discusses evolving treatment strategies for restless legs syndrome (RLS). He reviews the growing role of gabapentinoids as first-line therapy, explains concerns surrounding long-term dopamine agonist use, and highlights important considerations for monitoring safety and cognitive function during treatment. This interview took place at the 40th annual meeting of the Associated Professional Sleep Societies (APSS) congress in Baltimore, MD.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
